MoonLake Immunotherapeutics (MLTX): Total Liabilities
$119.95M
As of 2025-12-31
$145.75M
As of 2026-06-30
+145.8%
3-year compound annual growth
+96.0%
5-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $119.95M | +388.8% | 2026-02-25, Balance as of period end |
| 2024-12-31 | $24.54M | +88.1% | 2026-02-25, Balance as of period end |
| 2023-12-31 | $13.05M | +61.6% | 2025-02-26, Balance as of period end |
| 2022-12-31 | $8.08M | -62.1% | 2024-02-29, Balance as of period end |
| 2021-12-31 | $21.33M | +413.9% | 2023-03-20, Balance as of period end |
| 2020-12-31 | $4.15M | n/a | 2022-02-17, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| MoonLake Immunotherapeutics (MLTX) | 2025-12-31 | $119.95M | +388.8% |
| Stoke Therapeutics, Inc. (STOK) | 2025-12-31 | $65.98M | +55.1% |
| Bicara Therapeutics Inc. (BCAX) | 2025-12-31 | $29.54M | +63.0% |
| Arcutis Biotherapeutics, Inc. (ARQT) | 2025-12-31 | $243.49M | +27.3% |
| BGM Group Ltd. (BGM) | 2025-09-30 | $41.92M | +370.4% |
| Alumis Inc. (ALMS) | 2025-12-31 | $110.64M | +36.8% |
| Oric Pharmaceuticals, Inc. (ORIC) | 2025-12-31 | $24.53M | -20.9% |
| Nkarta, Inc. (NKTX) | 2025-12-31 | $91.88M | -1.4% |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | 2025-12-31 | $37.28M | +90.4% |
Compare MLTX, STOK, BCAX, ARQT side by side · Screen every company in Pharmaceutical Preparations ↗